Avalo Therapeutics, Inc. (AVTX)

NCM – Real Time Price. Currency in USD

19.38

-0.09 (-0.46%)

Market open: Aug 12, 2026, 12:58 PM EDT

19.47

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2026.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Avalo Therapeutics, Inc. (AVTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Videos

No Data

Press releases

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Videos

No Data

Press releases

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Search stocks

Avalo Therapeutics, Inc. (AVTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Videos

No Data

Press releases

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Videos

No Data

Press releases

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates